the cases receiving chemotherapy alone and those receiving chemoimmunotherapy, though the response rate was slightly higher in cases treated with the regimen of 5-FU+CHRM+OK-432 than in those treated with the regimen of 5-FU+ GHRM. Meanduration of response was 16 .0 weeks in the cases treated with FT-207 alone, 15.7 weeks with the regimen of FT-207+OK-432, ll.0 weeks with the regimen of 5-FU+CHRM, 24.0 weeks with the regimen of 5-FU+CHRM+OK -432, 7.5 weeks with the regimen of 5-FU+ADR, and ll.2 weeks with the regimen of 5-FU+ADR+LMS, respectively.
Therefore, it seems that longer duration of response was obtained by using chemoimmunotherapy than by using chemotherapy alone.
It was demonstrated also that performance status had a significant effect on objective response. Response was found in 19 of 69 cases (28%) with performance status of more than 40% (Karnofsky's scale).
On the contrary, cases with performance status of less than 40% had a reduced response rate (7%, 2/28).
Furthermore, general immune status of the patients was examined sequentially on the basis of various immunological parameters including the skin reactivities to PHAand PPD, T and B cell counts in peripheral blood, and the in vitro lymphocyte reactivities to PHA and PWM. Irrespective of chemoimmunotherapy or chemotherapy alone, there was a tendency to improve the immune status of the responders to the therapy. Ghemoimmunotherapy seems to prevent an impairment of immunestatus in the non-responders to the therapy.
(6) Prospect of Tumor Immunotherapy Yuichi Yamamura, MD The Third Deportment of Internal Medicine, Osaka University School of Medicine Tumor immunotherapy is defined as a following therapeutic modality of tumor.
1)
Anti-tumor activities should be observed in syngeneic or autochthonous tumors of experimental animals. 2) As to the mechanism of anti-tumor activities, immunological mechanism should be presented.
3 These results lead us to believe that BGG-GWS therapy is a therapeutic modality in favourably modifying the prognosis of patients with lung cancer. The next step is to find out new more active immunotherapeutic agents of cancer. The one is CWSof Nocardia, which is more active and less toxic than BCG-CWS. Nocardia is more easily cultivated within a few days than BCG.
The other is active immunopotentiating substance of synthetic subunit of GWS.
6-0-Mycoloyl-N-acetylmuramyl-L-alanyl-Disoglutamine was obtained as a synthetic compound having enhancing activities of cell-mediated cytotoxicity to tumor cells and antitumor activity to syngeneic transplantable tumors. Tumor immunotherapy is expected to develop on the basis of progress of basic immunology in the future.
